Sign in to view content

Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization

Jeffrey L. Olson, MD

Video
Published 2019

Jeffrey Olson, MD

Related

Two-Year Results of an Ongoing Phase 1b/2 Open-Label Clinical Trial of AU-011 for the Primary Treatment of Small to Medium Choroidal Melanoma
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2019
Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated With Vitreoretinal Surgery
Daniel F. Kiernan, MD, FACS
Annual Meeting Talks
2020
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more